News
02-10-2010, 10:50 PM
Shenogen Pharma Group and Chemizon, a division of Optomagic Co. Ltd. today announced a drug discovery collaboration agreement to create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
More... (http://www.news-medical.net/news/20100211/Shenogen-Pharma-Group-Chemizon-sign-drug-discovery-collaboration-agreement.aspx)
More... (http://www.news-medical.net/news/20100211/Shenogen-Pharma-Group-Chemizon-sign-drug-discovery-collaboration-agreement.aspx)